Daniel Eriksson

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Replacement Therapy

Juvenile Idiopathic Arthritis

Top Venues

Advances in therapy

Therapeutic advances in hematology

Journal of blood medicine

Open access rheumatology : research and reviews

This page only lists publications with an associated author ORCID identifier.

Publications

Priyanka Raheja, Nana Kragh, Linda Bystrická, Daniel Eriksson, Khaoula Aroui, Marwa Mezghani, Sylvaine Barbier, Silvia Linari
Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia A: post hoc analysis of phase III trials using patient-reported outcomes. Therapeutic advances in hematology 15 (2024)
Michal Pochopien, Anna Tytuła, Mondher Toumi, Aletta Falk, Nicoletta Martone, Zalmai Hakimi, Daniel Eriksson
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors. Advances in therapy (2024)
Michal Pochopien, Anna Tytuła, Mondher Toumi, Aletta Falk, Nicoletta Martone, Zalmai Hakimi, Daniel Eriksson
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors. Advances in therapy 41 (6) (2024)
Michal Pochopien, Anna Tytuła, Mondher Toumi, Aletta Falk, Nicoletta Martone, Zalmai Hakimi, Daniel Eriksson
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors. Advances in therapy 41 (6) (2024)
Michal Pochopien, Anna Tytuła, Mondher Toumi, Aletta Falk, Nicoletta Martone, Zalmai Hakimi, Daniel Eriksson
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors. Advances in therapy 41 (6) (2024)
Michal Pochopien, Anna Tytuła, Mondher Toumi, Aletta Falk, Nicoletta Martone, Zalmai Hakimi, Daniel Eriksson
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors. Advances in therapy 41 (6) (2024)
Priyanka Raheja, Nana Kragh, Linda Bystrická, Daniel Eriksson, Khaoula Aroui, Marwa Mezghani, Sylvaine Barbier, Silvia Linari
Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia A: post hoc analysis of phase III trials using patient-reported outcomes. Therapeutic advances in hematology 15 (2024)
Maria Elisa Mancuso, Daniel Eriksson, Aletta Falk, Zalmai Hakimi, Piotr Wojciechowski, Marlena Wdowiak, Robert Klamroth
Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials. Journal of blood medicine 14 (2023)
Eva Funding, Gillian Lowe, Lone H Poulsen, Susan Shapiro, Johannes Oldenburg, Daniel Eriksson, Aletta Falk, Carly Rich
Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries. Advances in therapy (2023)
Ash Bullement, Emma S Knowles, Merel Langenfeld, Gil Reynolds Diogo, Jameel Nazir, Daniel Eriksson
An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA). Open access rheumatology : research and reviews 13 (2021)